This review synthesizes emerging multi-omic and spatial evidence to delineate IGFBP-6 cell-of-origin, zonation, and regulation in the liver; integrates these data with stromal biology to propose mechanisms for disease-stage-specific roles; and outlines translational opportunities—from biomarker strategies to rational patient selection—in primary liver cancers. This evidence concerns the gene IGFBP6 and liver cancer.